Novo Nordisk
Tracked across 47 events · 467 articles · First seen Feb 02, 2025 · Last active Jun 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
NewsDesk Dashboard
Business
Impact: Novo Nordisk's CEO, Lars Fruergaard Jørgensen, is stepping down due to market challenges and a significant decline in its share price, impacting its leadership and market position in the obesity drug market.
May 16, 2025 · 7 articles
Business
Impact: Novo Nordisk announced significant job cuts and a revised profit outlook due to increased competition and slowing sales of its key weight-loss and diabetes drugs. The company aims to simplify its structure and reallocate resources for future growth.
Sep 10, 2025 · 6 articles
Business
Impact: Novo Nordisk partnered with Emcure Pharma to expand the distribution and marketing of its weight-loss drug semaglutide in India under the brand Poviztra, aiming to reach a wider population.
Nov 10, 2025 · 6 articles
Business
Impact: Novo Nordisk cut the price of its weight-loss drug Semaglutide in India to compete with Eli Lilly and prepare for generic competition, aiming to increase market share and accessibility.
Nov 11, 2025 · 6 articles
Regulatory
Impact: Novo Nordisk received United States — Food and Drug Administration approval for its Wegovy pill, gaining an edge in the obesity treatment market over Eli Lilly and Company. The company expects the pill to be available within weeks, with a starting dose of $149 per month.
Dec 22, 2025 · 23 articles
Business
Impact: Novo Nordisk launched its Wegovy pill in the United States, aiming to attract new consumers and regain market share in the competitive weight-loss drug market. This launch is expected to boost its fortunes after previous profit warnings and sliding shares.
Jan 05, 2026 · 7 articles
Tech
Impact: Novo Nordisk announced positive topline results from its HIBISCUS phase 3 trial for etavopivat, a drug for sickle cell disease, which is expected to lead to regulatory submission and potential market approval, significantly boosting the company's pipeline and market position.
Apr 20, 2026 · 7 articles
Business
Novo Nordisk initiated a share repurchase program on May 6, 2026, as part of an overall program to repurchase up to DKK 15 billion of its B shares over a 12-month period starting February 4,…
Impact: Novo Nordisk is repurchasing its own B shares, which is expected to support its stock price and return value to shareholders. This action reduces the number of outstanding shares, potentially increasing earnings per share.
May 26, 2026 · 6 articles
Regulatory
Parker Waichman LLP has filed multiple lawsuits against pharmaceutical giants Novo Nordisk and Eli Lilly and Company, alleging that their popular GLP-1 receptor agonist medications, Semaglutide, Semaglutide, Tirzepatide, and Tirzepatide, caused Non-Arteritic Anterior Ischemic Optic…
Impact: Novo Nordisk is a pharmaceutical company facing multiple lawsuits alleging that its GLP-1 medications, Semaglutide and Semaglutide, caused NAION and that the company failed to adequately warn consumers about these risks. This could lead to significant financial and reputational damage.
May 22, 2026 · 7 articles
Business
Impact: Novo Nordisk partnered with Costco to expand access and sales of its GLP-1 medications, Semaglutide and Semaglutide, at a standardized discounted price, combating competition from compounding pharmacies.
Oct 03, 2025 · 8 articles
Domestic
France has announced that it will begin reimbursing the cost of weight-loss drugs, specifically Novo Nordisk's Semaglutide and Eli Lilly and Company's Tirzepatide, for severely obese patients starting mid-June. This makes France the first European…
Impact: Novo Nordisk's drugs, Semaglutide and Tirzepatide, are among those that will be reimbursed in France, leading to increased market access and sales for the company in Europe. The company's General Manager and CEO welcomed the decision.
May 28, 2026 · 6 articles
Business
Impact: Novo Nordisk terminated its partnership with Hims & Hers Health due to the latter's deceptive promotion of 'knockoff' versions of Wegovy, protecting its brand and patient safety.
Jun 26, 2025 · 55 articles
Regulatory
Impact: Novo Nordisk agreed to lower prices for its obesity drug Wegovy, making it more accessible to United States — Medicare and United States — Medicaid recipients and those paying directly. The company's spokesperson declined to provide specific details on pricing changes.
Nov 06, 2025 · 6 articles
Regulatory
The United Arab Emirates — Emirates Drug Establishment (EDE) in the United Arab Emirates has approved Semaglutide (semaglutide), an oral once-daily treatment developed by Novo Nordisk, for long-term weight management in adults with obesity or…
Impact: Novo Nordisk developed Semaglutide (semaglutide), and its collaboration with the United Arab Emirates — Emirates Drug Establishment led to the approval of the oral formulation in the United Arab Emirates, expanding its market reach for this significant treatment.
Jun 01, 2026 · 6 articles
Tech
New research presented at the 2026 American Society of Clinical Oncology>>> Annual Meeting indicates that GLP-1 medications, widely used for weight loss and diabetes, may significantly reduce the risk of developing various cancers, including breast…
Impact: Novo Nordisk>>> produces GLP-1 drugs like Wegovy, Ozempic, Rybelsus, Saxenda, and Victoza, which are showing potential benefits in cancer prevention and treatment.
Jun 02, 2026 · 37 articles
Tech
Impact: Novo Nordisk produces Semaglutide and Semaglutide, which are GLP-1 agonist drugs. The research indicates that patients regain weight quickly after discontinuing these medications, potentially impacting long-term sales and cost-effectiveness assessments by health systems.
Jan 08, 2026 · 6 articles
Tech
Impact: Novo Nordisk, the manufacturer of Semaglutide, is facing scrutiny due to reports of severe adverse reactions experienced by Sarah-Jayne Crawford. They have issued a statement acknowledging gallstones as a common potential adverse reaction.
Apr 13, 2026 · 6 articles
Tech
A new study published in Tata Communications, led by Michael Francis Crotty of the University of California, San Diego, provides the first randomized, placebo-controlled clinical evidence that Semaglutide, a widely used GLP-1 drug, slows down…
Impact: Novo Nordisk is the manufacturer of Semaglutide, and the positive research findings could lead to expanded market opportunities and increased demand for their GLP-1 drugs.
Jun 02, 2026 · 6 articles
Business
Impact: Novo Nordisk has shown a more aggressive M&A approach following recent CEO transitions and has been advised on recent deals, indicating its participation in the acquisition spree.
May 01, 2026 · 6 articles
Tech
Global companies are increasingly leveraging AI at their Indian hubs to bring creative advertising work in-house, thereby reducing turnaround times and reliance on external agencies. Companies such as Kimberly-Clark, Catalyst Brands, and Oracle Corporation are…
Impact: Novo Nordisk's Bengaluru center is taking on a larger role in global drug launches, including preparatory work for its oral obesity pill in the United States. This indicates an increased strategic importance of its India operations.
May 26, 2026 · 12 articles
Tech
Global Capability Centres (GCCs) of multinational firms in India>>> are increasingly leveraging AI in diverse and innovative ways, moving beyond basic chatbots into core corporate functions. Companies like Apollo Hospitals>>> are using AI clinical assistants…
Impact: Novo Nordisk>>> is deploying AI across critical parts of the drug launch process, including drafting regulatory documents and analyzing safety data, aligning with global efforts to save costs.
May 28, 2026 · 6 articles
Business
Phemex, a crypto exchange, has expanded its TradFi ecosystem to include 73 active assets, integrating high-performance contracts from healthcare leaders like Eli Lilly and Company and Novo Nordisk, and semiconductor powerhouses such as Samsung Electronics…
Impact: Novo Nordisk is a healthcare leader whose contracts were integrated into Phemex's TradFi offering, allowing Phemex users to trade its assets continuously.
Jun 03, 2026 · 6 articles
Domestic
President Donald Trump>>> announced the second expansion of his administration's direct-to-consumer drug platform, TrumpRx, adding 160 prescription medications to bring the total to over 800. This initiative aims to provide discounted prices for four out…
Impact: Novo Nordisk>>> is participating in the TrumpRx program, agreeing to reduce prices on popular GLP-1 weight-loss medications.
Jun 06, 2026 · 8 articles
Tech
Impact: Novo Nordisk is a sponsor of World Hemophilia Day 2026, supporting the World Federation of Hemophilia's efforts.
Apr 17, 2026 · 6 articles
Business
Nxera Pharma Co., Ltd. announced on June 10, 2026, that it has joined OpenFold, a non-profit AI research consortium dedicated to developing open-source AI software tools for biology and drug discovery. This move aligns with…
Impact: Novo Nordisk is a pharmaceutical company that participates in the OpenFold consortium, benefiting from access to AI-enabled tools for drug discovery.
Jun 10, 2026 · 9 articles
+ 17 more events
View on Dashboard
100
Parker Waichman LLP filed lawsuits Novo NordiskParker Waichman Sues Novo...
95
Novo Nordisk produced drugsParker Waichman Sues Novo...
90
Novo Nordisk initiated share repurchaseNovo Nordisk B share repurchase
80
Novo Nordisk welcomed decisionFrance reimburses weight-loss drugs
75
Novo Nordisk expanded roleGlobal Firms Adopt AI in India
70
Novo Nordisk deploying AIIndia GCCs Drive AI Adoption
55
Novo Nordisk teased spotGLP-1 Drugs Reduce Cancer Risk
Hims & Hers Health
competitor
↔
Novo Nordisk
Novo Nordisk terminated its distribution partnership with Hims & Hers Health and
Hims & Hers Health
competitor
↔
Novo Nordisk
Hims & Hers Health is facing legal threats from Novo Nordisk after their brief d
NEWSDESK
Track Novo Nordisk live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard